公开(公告)号：EP2709609A4

公开(公告)日：2015-08-26

申请号：EP12785516

申请日：2012-05-16

申请人： SHIONOGI & CO ,  PURDUE PHARMA LP

发明人： KUROSE NORIYUKI ,  FUCHINO KOUKI ,  HATA KAYOKO ,  ISO YASUYOSHI ,  YAMAGUCHI NAOKO ,  SHAO BIN ,  TAFESSE LAYKEA ,  ZHOU XIAOMING ,  YU JIANMING

IPC分类号： A61K31/165 ,  A01N43/40 ,  A61K31/44 ,  A61K31/497

CPC分类号： C07D413/14 ,  C07D271/06 ,  C07D271/10 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/14

公开(公告)号：EP3148535A4

公开(公告)日：2017-11-29

申请号：EP15799729

申请日：2015-05-26

申请人： PURDUE PHARMA LP

发明人： YOUNGMAN MARK ,  TAFESSE LAYKEA ,  GOEHRING R RICHARD ,  YU JIANMING

IPC分类号： C07D471/20 ,  A61K31/4166 ,  A61P29/00

CPC分类号： C07D471/20 ,  C07B59/002 ,  C07B2200/05 ,  C07D489/09

摘要： In one aspect, the invention provides compounds of Formula I: (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, Y, Za are defined as set forth in the disclosure. The invention also provides compounds of any one of Formulae II to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof. Other aspects of the invention include the use of compounds of Formulae I to VII, IA to IC, and IIA to IIC, and pharmaceutically acceptable salts and solvates thereof for the treatment of disorders responsive to modulation of one or more opioid receptors. In certain embodiments, the Compounds of the Invention are useful for treating pain.

公开(公告)号：EP3139921A4

公开(公告)日：2018-02-14

申请号：EP15789868

申请日：2015-05-05

申请人： PURDUE PHARMA LP

发明人： TAFESSE LAYKEA ,  YAO JIANGCHAO ,  YU JIANMING ,  GOEHRING R RICHARD

IPC分类号： A61K31/439 ,  A61K31/485 ,  A61P29/00

CPC分类号： C07D221/26 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

摘要： The invention provides compounds as represented by Formula I or I' and pharmaceutically acceptable salts, solvates, and diastereomers thereof: Wherein R1, R2, R2a, R3, and R4 are defined in the disclosure. The invention also provides compounds of Formulae II, III, and A-H, and pharmaceutically acceptable salts, solvates, and diastereomers thereof. In certain embodiments, Compounds of the Invention are useful for treating pain, constipation, and other conditions as delineated in the disclosure. Without wishing to be bound by any theory, it is believed that Compounds of the Invention are effective in treating conditions that are modulated by activity of opioid and/or ORL-1 receptors.

公开(公告)号：EP3087059A4

公开(公告)日：2017-06-21

申请号：EP14875367

申请日：2014-08-22

申请人： PURDUE PHARMA LP

发明人： YU JIANMING

IPC分类号： C07D231/56 ,  A61K31/416 ,  A61P25/00 ,  A61P29/00 ,  C07D231/54

CPC分类号： C07D403/14 ,  A61K31/416 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/12 ,  C07D403/12

摘要： In one aspect, the present disclosure provides indazoles of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R3, R4, R5, R6, Z1, Z2, Z3, and G are defined as set forth in the specification. Further, the present disclosure also provides compounds of Formulae II and IA, and the pharmaceutically acceptable salts and solvates thereof. The present disclosure is also directed to the use of compounds of Formulae I, II, and IA, and the pharmaceutically acceptable salts and solvates thereof, to treat a disorder responsive to the blockade of sodium channels. In one embodiment, compounds of the present disclosure are especially useful for treating pain.

摘要翻译： 在一个方面，本公开提供了式I的吲唑：（I）及其药学上可接受的盐和溶剂合物，其中R 3，R 4，R 5，R 6，Z 1，Z 2，Z 3和G如说明书中所述 。 此外，本公开还提供了式II和IA的化合物及其药学上可接受的盐和溶剂化物。 本公开还涉及式I，II和IA的化合物及其药学上可接受的盐和溶剂合物在治疗对钠通道阻断响应的病症中的用途。 在一个实施方案中，本公开的化合物对于治疗疼痛特别有用。